Compare iShares China Large-Cap ETF (FXI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Johnson & Johnson — how do they compare? iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B), while Johnson & Johnson trades at $261.2 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 160.1× iShares China Large-Cap ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Johnson & Johnson for 129 Days on average.
| FXI | JNJ | |
|---|---|---|
Market Cap | $3.86B | $618.09B |
Volume | 16,323,837 | 6,050,983 |
52-Week High | $41.08 | $278.43 |
52-Week Low | $31.59 | $186.00 |
Typical Hold Time | 150 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.19, up 2.3% today, but technical indicators show a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent U.S.-China diplomatic engagement offers potential for reduced trade tensions, but momentum remains weak with the ETF trading near key support at $33.
FXI presents a value opportunity trading at half the S&P 500's P/E ratio with a 1.98% yield, but requires tolerance for significant geopolitical risk. The ETF's heavy financial sector exposure and China's export-driven economy face protectionism threats, making it suitable only for diversified portfolios with high risk tolerance.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
